Trial · NCT03905135
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Interleukin 15 | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | NA | mcg/kg | ||
| Maximum Tolerated Dose (MTD) of Interleukin 15 | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | NA | mcg/kg | ||
| Mean Progression Free Survival (PFS) | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | 303 | Standard Deviation 242 | Days | |
| Mean Progression Free Survival (PFS) | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | 61.5 | Standard Deviation 55.9 | Days | |
| Mean Event-free Survival (EFS) | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | 176 | Standard Deviation 140 | Days | |
| Mean Event-free Survival (EFS) | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | 33.54 | Standard Deviation 0.98 | Days | |
| Mean Overall Survival (OS) | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | 529 | Standard Deviation 345 | Days | |
| Mean Overall Survival (OS) | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | 300 | Standard Deviation 430 | Days | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Partial Response | 2 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Partial Response | 0 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Progressive Disease | 2 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Progressive Disease | 2 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Stable Disease | 2 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Stable Disease | 0 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Minor Response | 0 | Participants | |
| Overall Response in Participants With Greater Than or Equal to 50% Programmed Death-ligand 1 (PD-L1) Expressing Tumor Cells | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Minor Response | 0 | Participants | |
| Number of Participants With Overall Best Response | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Complete Response | 0 | Participants | |
| Number of Participants With Overall Best Response | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Complete Response | 0 | Participants | |
| Number of Participants With Overall Best Response | Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab | Partial Response | 2 | Participants | |
| Number of Participants With Overall Best Response | Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab | Partial Response | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03905135/results